MK-677 (ibutamoren) is an oral growth-hormone secretagogue, not a true peptide. See what the evidence and 2026 legal status say, why it's banned in sport, and what to ask clinics that reference it. This page is informational and does not diagnose, prescribe, or recommend therapies.
Looking for clinics by city? Explore peptide clinics in Miami , Los Angeles, and New York to compare verified providers by treatment focus.
Recovery peptide users often compare BPC-157 and TB-500, while metabolic health users usually cross-reference semaglutide.
MK-677 pages attract users comparing growth-hormone and performance options. The strongest clinics explain the evidence limits, the WADA ban, and the metabolic side effects honestly rather than marketing it as an easy growth-hormone shortcut.
This page is useful for people researching performance, recovery, and hormone-optimisation clinics that reference MK-677 — and for athletes who need to understand its anti-doping status.
MK-677 pricing varies and is usually bundled into a wider programme. Compare what clinical oversight and monitoring are included rather than the headline cost.
MK-677, also known as ibutamoren, is an orally active compound that stimulates the body's own release of growth hormone and IGF-1 by mimicking the hormone ghrelin. Despite often being grouped with peptide therapies, it is not actually a peptide. It is not an approved medicine: it reached early clinical trials but was never approved for sale. In the United States it had been placed in the FDA's restricted 503A compounding category and was removed from that restricted list in April 2026 pending a fresh review — which is not the same as approval. In the United Kingdom the MHRA treats it as an unlicensed substance generally sold as a 'research chemical', and it is prohibited in sport at all times under the WADA list.
MK-677 works by mimicking ghrelin and acting on receptors that prompt the pituitary gland to release more growth hormone, which in turn raises IGF-1. Most of what is known comes from limited clinical and laboratory research rather than large long-term human trials, so claims about body-composition or anti-aging benefits should be read cautiously. Reported effects also include increased appetite, water retention, and changes in blood sugar and insulin sensitivity, which is part of why supervision matters. For someone comparing clinics, the useful question is whether a provider explains those trade-offs honestly.
MK-677 is usually folded into a broader performance, recovery, or longevity programme rather than priced alone, so clinician involvement, monitoring (including blood-sugar checks), and sourcing transparency are more meaningful than the headline figure. See the peptide therapy cost guide.
Because MK-677 is not an approved medicine and long-term human safety data is limited, its risks in healthy people are not well characterised; reported effects on appetite, water retention, and blood sugar mean it should only be considered with proper clinical supervision and monitoring. It is also banned in tested sport. This page does not recommend MK-677 and does not provide dosing or administration guidance.
Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.
No. MK-677 (ibutamoren) is not a steroid. It is an orally active growth-hormone secretagogue that mimics ghrelin to stimulate the body's own growth-hormone release. It is also not technically a peptide, although it is often grouped with peptide therapies.
MK-677 is not an approved medicine. In the UK the MHRA treats it as unlicensed, and in the US it is not FDA-approved and is sold as a 'research chemical' not intended for human consumption. It is not a DEA-scheduled controlled substance.
Yes. MK-677 is prohibited at all times under the WADA list, in and out of competition. Any athlete subject to drug testing should treat it as a banned substance.
Commonly reported effects include increased appetite, water retention, and changes in blood sugar and insulin sensitivity. Because long-term human data is limited, it should only be considered under clinical supervision with monitoring.
MK-677 reached early clinical trials but was never approved, and long-term studies in healthy people are limited. Claims of strong body-composition or anti-aging benefits should be treated with caution.
No. Peptide Clinic Finder is an informational directory. We do not sell MK-677, provide medical advice, or recommend its use — we help you compare how clinics position and supervise treatments so you can make an informed decision with a licensed clinician.
Related comparisons: MK-677 vs Ipamorelin, MK-677 vs HGH.
Next step
If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.
Move from peptide research into clinic comparisons, guides, and matching.
Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.
Move from treatment research into provider comparison by choosing the next step that fits your buying journey. Some users want to compare programmes first, while others want a faster route into matched options or local clinic discovery.
Next step
Move from peptide research into real provider comparison by checking city pages, cost context, and related treatment comparisons. Clinics vary more by oversight and programme structure than by peptide name alone.
For clinics
Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.